Doszklistkowe zastosowanie ranimizumabu (Lucentis) w leczeniu retinopatii wcześniaków - opis przypadku
Intravitreal Ranimizumab (Lucentis) Injection in Retinopathy of Prematurity Treatment - Case Report
Małgorzata Seroczyńska, Mirosława Grałek, Beta Kocyła-Karczmarewicz, Wojciech Hautz, Krystyna Kanigowska
Klinika Okulistyki Instytutu „Pomnik – Centrum Zdrowia Dziecka” w Warszawie
Kierownik: prof. dr hab. n. med. Mirosława Grałek
Summary: Purpose: To present the course of aggressive stage of retinopathy of prematurity treated with intravitreal ranimizumab (Lucentis) injections in preterm children.
Material and Methods: A male patient, born at 24 weeks gestation with a birth weight of 710 g, with severe stage of retinopathy of prematurity (ROP 3 „plus”) in zone I, had three times laser photocoagulation (in week 10, 11 and 13). Because ROP progressed, in 18th week of live the boy received intravitreal injection of 0.25 mg ranimizumad (Lucentis) to each eye. The treatment was administered during general anesthesia.
Results: Treatment had resulted in ROP regression in both eyes, prompt resolution of plus signs and neovascular proliferation. The eyes were treated successfully (no retinal detachment or other ocular abnormalities) with only 1 injection. No complications (local or systemic) were observed.
Conclusions: Intravitreal ranimizumab injection was effective and safe in treating stage 3 ROP ”plus” in zone I.
Słowa kluczowe: retinopatia wcześniaków, laseroterapia, terapia anty-VEGF, ranibizumab, leczenie ratujące.
Keywords: retinopathy of prematurity, laser therapy, anti-VEGF therapy, ranibizumab, salvage treatment.